Inhibition of transforming growth factor-β activation diminishes tumor progression and osteolytic bone disease in mouse models of multiple myeloma

American Journal of Pathology

Volumn 186, Issue 3, 2016, Pages 678-690

  Lu, Ailing ^a   Pallero, Manuel A ^a   Lei, Weiqi ^a   Hong, Huixian ^a   Yang, Yang ^a   Suto, Mark J ^b   Murphy Ullrich, Joanne E ^a  

^a University of Alabama at Birmingham   (United States)

^b SOUTHERN RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; ANTINEOPLASTIC AGENT; BORTEZOMIB; DEXAMETHASONE; HEPARANASE; IMMUNOGLOBULIN G2B; IMMUNOGLOBULIN KAPPA CHAIN; INTERLEUKIN 6; SMAD2 PROTEIN; SRI 31277; TARTRATE RESISTANT ACID PHOSPHATASE 5B; THROMBOSPONDIN 1; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; INTERLEUKIN-6, MOUSE; LEU-SER-LYS-LEU PEPTIDE; PEPTIDE; SRI31277; THROMBOSPONDIN-1, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE DENSITY; BONE DESTRUCTION; BONE DISEASE; CANCER GROWTH; CANCER INHIBITION; CANCER SIZE; CELL ACTIVATION; CELL COUNT; CELL GROWTH; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENTIATION; DRUG STABILITY; ENZYME ACTIVATION; ENZYME BLOOD LEVEL; ENZYME INHIBITION; ENZYME REGULATION; GENE OVEREXPRESSION; GROWTH INHIBITION; HUMAN; HUMAN CELL; IC50; IMMUNOGLOBULIN BLOOD LEVEL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; MULTIPLE MYELOMA; MULTIPLE MYELOMA CELL LINE; NONHUMAN; OSTEOBLAST; OSTEOCLAST; OSTEOLYTIC BONE DISEASE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; SEVERE COMBINED IMMUNODEFICIENCY; SIGNAL TRANSDUCTION; STROMA CELL; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR MICROENVIRONMENT; ANIMAL; ANTAGONISTS AND INHIBITORS; BONE DEVELOPMENT; C57BL MOUSE; CELL DIFFERENTIATION; DISEASE MODEL; DRUG EFFECTS; METABOLISM; OSTEOLYSIS; PATHOLOGY; RANDOMIZATION; SCID MOUSE;

ANIMALS; ANTINEOPLASTIC AGENTS; BORTEZOMIB; CELL DIFFERENTIATION; DISEASE MODELS, ANIMAL; HUMANS; INTERLEUKIN-6; MALE; MICE; MICE, INBRED C57BL; MICE, SCID; MULTIPLE MYELOMA; OSTEOGENESIS; OSTEOLYSIS; PEPTIDES; RANDOM ALLOCATION; SIGNAL TRANSDUCTION; THROMBOSPONDIN 1; TRANSFORMING GROWTH FACTOR BETA; TUMOR MICROENVIRONMENT;

EID: 84959016632     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.1016/j.ajpath.2015.11.003     Document Type: Article

References (56)

1. K.C. Anderson, and R.D. Carrasco Pathogenesis of myeloma Annu Rev Pathol 6 2011 249 274
2. K. Takeuchi, M. Abe, M. Hiasa, A. Oda, H. Amou, S. Kido, T. Harada, O. Tanaka, H. Miki, S. Nakamura, A. Nakano, K. Kagawa, K. Yata, S. Ozaki, and T. Matsumoto TGF-Beta inhibition restores terminal osteoblast differentiation to suppress myeloma growth PLoS One 5 2010 e9870
3. M. Urashima, A. Ogata, D. Chauhan, M. Hatziyanni, M.B. Vidriales, D.A. Dedera, R.L. Schlossman, and K.C. Anderson Transforming growth factor-beta1: differential effects on multiple myeloma versus normal B cells Blood 87 1996 1928 1938
4. I. Isufi, M. Seetharam, L. Zhou, D. Sohal, J. Opalinska, P. Pahanish, and A. Verma Transforming growth factor-beta signaling in normal and malignant hematopoiesis J Interferon Cytokine Res 27 2007 543 552
5. T. Matsumoto, and M. Abe TGF-beta-related mechanisms of bone destruction in multiple myeloma Bone 48 2011 129 134
6. R. Brown, A. Murray, B. Pope, D.M. Sze, J. Gibson, P.J. Ho, D. Hart, and D. Joshua Either interleukin-12 or interferon-gamma can correct the dendritic cell defect induced by transforming growth factor beta in patients with myeloma Br J Haematol 125 2004 743 748
7. T. Hayashi, T. Hideshima, A.N. Nguyen, O. Munoz, K. Podar, M. Hamasaki, K. Ishitsuka, H. Yasui, P. Richardson, S. Chakravarty, A. Murphy, D. Chauhan, L.S. Higgins, and K.C. Anderson Transforming growth factor beta receptor I kinase inhibitor down-regulates cytokine secretion and multiple myeloma cell growth in the bone marrow microenvironment Clin Cancer Res 10 2004 7540 7546
8. J. Wen, W. Tao, I. Kuiatse, P. Lin, Y. Feng, R.J. Jones, R.Z. Orlowski, and Y. Zu Dynamic balance of multiple myeloma clonogenic side population cell percentages controlled by environmental conditions Int J Cancer 136 2015 991 1002
9. E.C. Breen, R.A. Ignotz, L. McCabe, J.L. Stein, G.S. Stein, and J.B. Lian TGF beta alters growth and differentiation related gene expression in proliferating osteoblasts in vitro, preventing development of the mature bone phenotype J Cell Physiol 160 1994 323 335
10. M. Ruan, L. Pederson, E.W. Bradley, A.M. Bamberger, and M.J. Oursler Transforming growth factor-{beta} coordinately induces suppressor of cytokine signaling 3 and leukemia inhibitory factor to suppress osteoclast apoptosis Endocrinology 151 2010 1713 1722
11. A. Gingery, E.W. Bradley, L. Pederson, M. Ruan, N.J. Horwood, and M.J. Oursler TGF-beta coordinately activates TAK1/MEK/AKT/NFkB and SMAD pathways to promote osteoclast survival Exp Cell Res 314 2008 2725 2738
12. M.A. Frassanito, L. Rao, M. Moschetta, R. Ria, L. Di Marzo, A. De Luisi, V. Racanelli, I. Catacchio, S. Berardi, A. Basile, E. Menu, S. Ruggieri, B. Nico, D. Ribatti, R. Fumarulo, F. Dammacco, K. Vanderkerken, and A. Vacca Bone marrow fibroblasts parallel multiple myeloma progression in patients and mice: in vitro and in vivo studies Leukemia 28 2014 904 916
13. I. Bruns, R.P. Cadeddu, I. Brueckmann, J. Frobel, S. Geyh, S. Bust, J.C. Fischer, F. Roels, C.M. Wilk, F.A. Schildberg, A.N. Hunerliturkoglu, C. Zilkens, M. Jager, U. Steidl, F. Zohren, R. Fenk, G. Kobbe, B. Brors, A. Czibere, T. Schroeder, A. Trumpp, and R. Haas Multiple myeloma-related deregulation of bone marrow-derived CD34+ hematopoietic stem and progenitor cells Blood 120 2012 2620 2630
14. R.A. Flavell, S. Sanjabi, S.H. Wrzesinski, and P. Licona-Limon The polarization of immune cells in the tumour environment by TGFbeta Nat Rev Immunol 10 2010 554 567
15. J.P. Annes, J.S. Munger, and D.B. Rifkin Making sense of latent TGFbeta activation J Cell Sci 116 2003 217 224
16. P.J. Wipff, and B. Hinz Integrins and the activation of latent transforming growth factor beta1: an intimate relationship Eur J Cell Biol 87 2008 601 615
17. J.E. Murphy-Ullrich, and M. Poczatek Activation of latent TGF-beta by thrombospondin-1: mechanisms and physiology Cytokine Growth Factor Rev 11 2000 59 69
18. M.T. Sweetwyne, and J.E. Murphy-Ullrich Thrombospondin1 in tissue repair and fibrosis: TGF-beta-dependent and independent mechanisms Matrix Biol 31 2012 178 186
19. J.E. Murphy-Ullrich, and E.H. Sage Revisiting the matricellular concept Matrix Biol 37 2014 1 14
20. O. Stenina-Adognravi Invoking the power of thrombospondins: regulation of thrombospondins expression Matrix Biol 37 2014 69 82
21. N.M. Rogers, M. Sharifi-Sanjani, G. Csanyi, P.J. Pagano, and J.S. Isenberg Thrombospondin-1 and CD47 regulation of cardiac, pulmonary and vascular responses in health and disease Matrix Biol 37 2014 92 101
22. P. Ludek, S. Hana, A. Zdenek, A. Martina, K. Dana, B. Tomas, K. Lucie, K. Marta, M. Jaroslav, P. Miroslav, V. Jiri, and H. Roman Treatment response to bortezomib in multiple myeloma correlates with plasma hepatocyte growth factor concentration and bone marrow thrombospondin concentration Eur J Haematol 84 2010 332 336
23. J.M. Rendtlew Danielsen, L.M. Knudsen, I.M. Dahl, M. Lodahl, and T. Rasmussen Dysregulation of CD47 and the ligands thrombospondin 1 and 2 in multiple myeloma Br J Haematol 138 2007 756 760
24. A. Kukreja, S. Radfar, B.H. Sun, K. Insogna, and M.V. Dhodapkar Dominant role of CD47-thrombospondin-1 interactions in myeloma-induced fusion of human dendritic cells: implications for bone disease Blood 114 2009 3413 3421
25. J.E. Murphy-Ullrich, and R.V. Iozzo Thrombospondins in physiology and disease: new tricks for old dogs Matrix Biol 31 2012 152 154
26. S.M. Ribeiro, M. Poczatek, S. Schultz-Cherry, M. Villain, and J.E. Murphy-Ullrich The activation sequence of thrombospondin-1 interacts with the latency-associated peptide to regulate activation of latent transforming growth factor-beta J Biol Chem 274 1999 13586 13593
27. G.D. Young, and J.E. Murphy-Ullrich Molecular interactions that confer latency to transforming growth factor-beta J Biol Chem 279 2004 38032 38039
28. K.O. Yee, M. Streit, T. Hawighorst, M. Detmar, and J. Lawler Expression of the type-1 repeats of thrombospondin-1 inhibits tumor growth through activation of transforming growth factor-beta Am J Pathol 165 2004 541 552
29. S.E. Crawford, V. Stellmach, J.E. Murphy-Ullrich, S.M. Ribeiro, J. Lawler, R.O. Hynes, G.P. Boivin, and N. Bouck Thrombospondin-1 is a major activator of TGF-beta1 in vivo Cell 93 1998 1159 1170
30. S. Belmadani, J. Bernal, C.C. Wei, M.A. Pallero, L. Dell'italia, J.E. Murphy-Ullrich, and K.H. Berecek A thrombospondin-1 antagonist of transforming growth factor-beta activation blocks cardiomyopathy in rats with diabetes and elevated angiotensin II Am J Pathol 171 2007 777 789
31. A. Lu, M. Miao, T.R. Schoeb, A. Agarwal, and J.E. Murphy-Ullrich Blockade of TSP1-dependent TGF-beta activity reduces renal injury and proteinuria in a murine model of diabetic nephropathy Am J Pathol 178 2011 2573 2586
32. A. Ueno, Y. Miwa, K. Miyoshi, T. Horiguchi, H. Inoue, I. Ruspita, K. Abe, K. Yamashita, E. Hayashi, and T. Noma Constitutive expression of thrombospondin 1 in MC3T3-E1 osteoblastic cells inhibits mineralization J Cell Physiol 209 2006 322 332
33. K. Bailey Dubose, M. Zayzafoon, and J.E. Murphy-Ullrich Thrombospondin-1 inhibits osteogenic differentiation of human mesenchymal stem cells through latent TGF-beta activation Biochem Biophys Res Commun 422 2012 488 493
34. M. Borset, O. Hjertner, S. Yaccoby, J. Epstein, and R.D. Sanderson Syndecan-1 is targeted to the uropods of polarized myeloma cells where it promotes adhesion and sequesters heparin-binding proteins Blood 96 2000 2528 2536
35. Y. Yang, V. Macleod, M. Bendre, Y. Huang, A.M. Theus, H.Q. Miao, P. Kussie, S. Yaccoby, J. Epstein, L.J. Suva, T. Kelly, and R.D. Sanderson Heparanase promotes the spontaneous metastasis of myeloma cells to bone Blood 105 2005 1303 1309
36. B.O. Oyajobi, G. Franchin, P.J. Williams, D. Pulkrabek, A. Gupta, S. Munoz, B. Grubbs, M. Zhao, D. Chen, B. Sherry, and G.R. Mundy Dual effects of macrophage inflammatory protein-1alpha on osteolysis and tumor burden in the murine 5TGM1 model of myeloma bone disease Blood 102 2003 311 319
37. S. Schultz-Cherry, and J.E. Murphy-Ullrich Thrombospondin causes activation of latent transforming growth factor-beta secreted by endothelial cells by a novel mechanism (published correction appears in J Cell Biol 1993;122[5]:following 1143) J Cell Biol 122 1993 923 932
38. D.S. Annis, J.E. Murphy-Ullrich, and D.F. Mosher Function-blocking antithrombospondin-1 monoclonal antibodies J Thromb Haemost 4 2006 459 468
39. I.R. Garrett, S. Dallas, J. Radl, and G.R. Mundy A murine model of human myeloma bone disease Bone 20 1997 515 520
40. T. Kelly, H.Q. Miao, Y. Yang, E. Navarro, P. Kussie, Y. Huang, V. MacLeod, J. Casciano, L. Joseph, F. Zhan, M. Zangari, B. Barlogie, J. Shaughnessy, and R.D. Sanderson High heparanase activity in multiple myeloma is associated with elevated microvessel density Cancer Res 63 2003 8749 8756
41. A. Purushothaman, D.R. Hurst, C. Pisano, S. Mizumoto, K. Sugahara, and R.D. Sanderson Heparanase-mediated loss of nuclear syndecan-1 enhances histone acetyltransferase (HAT) activity to promote expression of genes that drive an aggressive tumor phenotype J Biol Chem 286 2011 30377 30383
42. Y. Yang, Y. Ren, V.C. Ramani, L. Nan, L.J. Suva, and R.D. Sanderson Heparanase enhances local and systemic osteolysis in multiple myeloma by upregulating the expression and secretion of RANKL Cancer Res 70 2010 8329 8338
43. C. Weiss, O. Uziel, O. Wolach, J. Nordenberg, E. Beery, S. Bulvick, G. Kanfer, O. Cohen, R. Ram, M. Bakhanashvili, H. Magen-Nativ, N. Shilo, and M. Lahav Differential downregulation of telomerase activity by bortezomib in multiple myeloma cells-multiple regulatory pathways in vitro and ex vivo Br J Cancer 107 2012 1844 1852
44. N.V. Sherbina, and P. Bornstein Modulation of thrombospondin gene expression during osteoblast differentiation in MC3T3-E1 cells Bone 13 1992 197 201
45. A.I. Alford, and K.D. Hankenson Matricellular proteins: extracellular modulators of bone development, remodeling, and regeneration Bone 38 2006 749 757
46. J.A. Carron, S.C. Wagstaff, J.A. Gallagher, and W.B. Bowler A CD36-binding peptide from thrombospondin-1 can stimulate resorption by osteoclasts in vitro Biochem Biophys Res Commun 270 2000 1124 1127
47. S.R. Amend, O. Uluckan, M. Hurchla, D. Leib, D.V. Novack, M. Silva, W. Frazier, and K.N. Weilbaecher Thrombospondin-1 regulates bone homeostasis through effects on bone matrix integrity and nitric oxide signaling in osteoclasts J Bone Miner Res 30 2015 106 115
48. T. Yehualaeshet, R. O'Connor, J. Green-Johnson, S. Mai, R. Silverstein, J.E. Murphy-Ullrich, and N. Khalil Activation of rat alveolar macrophage-derived latent transforming growth factor beta-1 by plasmin requires interaction with thrombospondin-1 and its cell surface receptor, CD36 Am J Pathol 155 1999 841 851
49. J.G. Harpel, S. Schultz-Cherry, J.E. Murphy-Ullrich, and D.B. Rifkin Tamoxifen and estrogen effects on TGF-beta formation: role of thrombospondin-1, alphavbeta3, and integrin-associated protein Biochem Biophys Res Commun 284 2001 11 14
50. B.H. Johnson, M. Gomi, S.B. Jakowlew, K. Moriwaki, and E.B. Thompson Actions and interactions of glucocorticoids and transforming growth factor beta on two related human myeloma cell lines Cell Growth Differ 4 1993 25 30
51. G.M. Mutlu, G.R. Budinger, M. Wu, A.P. Lam, A. Zirk, S. Rivera, D. Urich, S.E. Chiarella, L.H. Go, A.K. Ghosh, M. Selman, A. Pardo, J. Varga, D.W. Kamp, N.S. Chandel, J.I. Sznajder, and M. Jain Proteasomal inhibition after injury prevents fibrosis by modulating TGF-beta(1) signalling Thorax 67 2012 139 146
52. K. Shibahara, M. Ota, M. Horiguchi, K. Yoshinaga, J. Melamed, and D.B. Rifkin Production of gastrointestinal tumors in mice by modulating latent TGF-beta1 activation Cancer Res 73 2013 459 468
53. M. Abe, K. Hiura, S. Ozaki, S. Kido, and T. Matsumoto Vicious cycle between myeloma cell binding to bone marrow stromal cells via VLA-4-VCAM-1 adhesion and macrophage inflammatory protein-1alpha and MIP-1beta production J Bone Miner Metab 27 2009 16 23
54. V. Longo, O. Brunetti, S. D'Oronzo, F. Dammacco, and F. Silvestris Therapeutic approaches to myeloma bone disease: an evolving story Cancer Treat Rev 38 2012 787 797
55. E.C. Connolly, E.F. Saunier, D. Quigley, M.T. Luu, A. De Sapio, B. Hann, J.M. Yingling, and R.J. Akhurst Outgrowth of drug-resistant carcinomas expressing markers of tumor aggression after long-term TbetaRI/II kinase inhibition with LY2109761 Cancer Res 71 2011 2339 2349
56. G.J. Prud'homme Pathobiology of transforming growth factor beta in cancer, fibrosis and immunologic disease, and therapeutic considerations Lab Invest 87 2007 1077 1091